JP2019506841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506841A5 JP2019506841A5 JP2018528327A JP2018528327A JP2019506841A5 JP 2019506841 A5 JP2019506841 A5 JP 2019506841A5 JP 2018528327 A JP2018528327 A JP 2018528327A JP 2018528327 A JP2018528327 A JP 2018528327A JP 2019506841 A5 JP2019506841 A5 JP 2019506841A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- single variable
- immunoglobulin single
- variable domain
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 108060003951 Immunoglobulin Proteins 0.000 claims 22
- 102000018358 immunoglobulin Human genes 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 11
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197999 | 2015-12-04 | ||
| EP15197999.4 | 2015-12-04 | ||
| PCT/EP2016/079575 WO2017093478A1 (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113792A Division JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506841A JP2019506841A (ja) | 2019-03-14 |
| JP2019506841A5 true JP2019506841A5 (2) | 2019-04-25 |
| JP6728355B2 JP6728355B2 (ja) | 2020-07-22 |
Family
ID=54782606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528327A Active JP6728355B2 (ja) | 2015-12-04 | 2016-12-02 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
| JP2020113792A Withdrawn JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113792A Withdrawn JP2020178701A (ja) | 2015-12-04 | 2020-07-01 | 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10597449B2 (2) |
| EP (2) | EP3383425B1 (2) |
| JP (2) | JP6728355B2 (2) |
| KR (1) | KR102802241B1 (2) |
| CN (1) | CN108289943B (2) |
| AR (1) | AR106949A1 (2) |
| AU (1) | AU2016363787B2 (2) |
| BR (1) | BR112018010537A2 (2) |
| CL (1) | CL2018001384A1 (2) |
| CO (1) | CO2018005680A2 (2) |
| CY (1) | CY1123454T1 (2) |
| DK (1) | DK3383425T3 (2) |
| EA (1) | EA201891331A1 (2) |
| ES (1) | ES2821099T3 (2) |
| HR (1) | HRP20201528T1 (2) |
| HU (1) | HUE051777T2 (2) |
| IL (1) | IL259119B (2) |
| LT (1) | LT3383425T (2) |
| MA (2) | MA43368B1 (2) |
| MX (1) | MX380414B (2) |
| MY (1) | MY200933A (2) |
| PE (1) | PE20181515A1 (2) |
| PH (1) | PH12018501155B1 (2) |
| PL (1) | PL3383425T3 (2) |
| PT (1) | PT3383425T (2) |
| RS (1) | RS60823B1 (2) |
| SA (1) | SA518391728B1 (2) |
| SG (1) | SG11201804510PA (2) |
| SI (1) | SI3383425T1 (2) |
| TW (1) | TWI734719B (2) |
| UA (1) | UA122079C2 (2) |
| WO (1) | WO2017093478A1 (2) |
| ZA (1) | ZA201802867B (2) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2820151B1 (en) | 2012-02-28 | 2020-03-25 | Novartis AG | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| KR102802241B1 (ko) * | 2015-12-04 | 2025-05-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| PL3630816T3 (pl) * | 2017-05-31 | 2024-08-05 | Boehringer Ingelheim International Gmbh | Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20200106495A (ko) | 2017-11-29 | 2020-09-14 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료요법을 위한 조성물 및 방법 |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| CA3104526A1 (en) * | 2018-07-05 | 2020-01-09 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| BR112021016520A2 (pt) | 2019-03-29 | 2021-10-26 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| TW202104258A (zh) | 2019-03-29 | 2021-02-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗癌組合療法 |
| JP2022532868A (ja) | 2019-05-04 | 2022-07-20 | インヒブルクス インコーポレイテッド | Ｃｄ１２３結合性ポリペプチド及びその使用 |
| CA3139512A1 (en) * | 2019-05-08 | 2020-11-12 | Inhibrx, Inc. | Cd123 targeted immunotherapies |
| KR20220078568A (ko) * | 2019-08-14 | 2022-06-10 | 모드맵 테라퓨틱스 인코포레이티드 | Lrp5 단백질에 결합하는 항체 및 사용 방법 |
| AU2020331424A1 (en) * | 2019-08-14 | 2022-03-31 | Antlera Therapeutics Inc. | Antibodies that bind to LRP6 proteins and methods of use |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
| WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| EP4314075A4 (en) | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CD3 |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| WO2024147897A2 (en) * | 2023-01-05 | 2024-07-11 | Harpoon Therapeutics, Inc. | Trop2 targeting trispecific protein for treatment of cancer |
| CN116375851B (zh) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6528054B1 (en) * | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| WO2007140410A2 (en) * | 2006-05-30 | 2007-12-06 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (lrp6) as a mammary stem cell marker and related methods |
| EP2447558B1 (en) | 2006-06-08 | 2013-05-29 | NSK Ltd. | Method for manufacturing a drawn cup needle roller bearing having a seal ring |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN100428934C (zh) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| CA2671581A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| KR20100091170A (ko) | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법 |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| EP2268668A1 (en) | 2008-04-17 | 2011-01-05 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
| US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
| CA2777527C (en) | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| UY33253A (es) | 2010-03-03 | 2011-09-30 | Boehringer Ingelheim Int | Polipéptidos de unión a a-beta |
| AR080795A1 (es) | 2010-03-24 | 2012-05-09 | Genentech Inc | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) |
| EP4234698A3 (en) | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| KR20130066631A (ko) * | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법 |
| EP2630154A1 (en) * | 2010-10-20 | 2013-08-28 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating the wnt pathway |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| DK2723769T4 (da) | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| SG2014010482A (en) | 2011-08-17 | 2014-04-28 | Glaxo Group Ltd | Modified proteins and peptides |
| CN104039830A (zh) | 2011-11-04 | 2014-09-10 | 诺华股份有限公司 | 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体 |
| JP5949270B2 (ja) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム |
| WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
| KR102802241B1 (ko) | 2015-12-04 | 2025-05-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드 |
-
2016
- 2016-12-02 KR KR1020187019053A patent/KR102802241B1/ko active Active
- 2016-12-02 MA MA43368A patent/MA43368B1/fr unknown
- 2016-12-02 HR HRP20201528TT patent/HRP20201528T1/hr unknown
- 2016-12-02 TW TW105139826A patent/TWI734719B/zh active
- 2016-12-02 MX MX2018006760A patent/MX380414B/es unknown
- 2016-12-02 EA EA201891331A patent/EA201891331A1/ru unknown
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/zh active Active
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/ja active Active
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en not_active Ceased
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 PT PT168089712T patent/PT3383425T/pt unknown
- 2016-12-02 MA MA054648A patent/MA54648A/fr unknown
- 2016-12-02 PH PH1/2018/501155A patent/PH12018501155B1/en unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/pl unknown
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/lt unknown
- 2016-12-02 UA UAA201807120A patent/UA122079C2/uk unknown
- 2016-12-02 RS RS20201124A patent/RS60823B1/sr unknown
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/es unknown
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/pt active IP Right Grant
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/hu unknown
- 2016-12-02 ES ES16808971T patent/ES2821099T3/es active Active
- 2016-12-02 AR ARP160103720A patent/AR106949A1/es unknown
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/da active
- 2016-12-02 SI SI201630953T patent/SI3383425T1/sl unknown
-
2018
- 2018-05-02 ZA ZA2018/02867A patent/ZA201802867B/en unknown
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/es unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/es unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/ar unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/ja not_active Withdrawn
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506841A5 (2) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| JP2018527919A5 (2) | ||
| JP2017506217A5 (2) | ||
| JP2018537421A5 (2) | ||
| JP2022502371A5 (2) | ||
| JP2016539096A5 (2) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| JP2019522490A5 (2) | ||
| JP2020521478A5 (2) | ||
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2016053091A5 (2) | ||
| JP2018508483A5 (2) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2017529067A5 (2) | ||
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2019511212A5 (2) | ||
| JP2016536322A5 (2) | ||
| JP2017500018A5 (2) | ||
| JP2009505676A5 (2) | ||
| JP2018508509A5 (2) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2018512856A5 (2) |